Dhaneesha N. S. Senaratne

Dhaneesha N. S. Senaratne

Auto-generated profile, based on publicly available information

Dhaneesha N. S. Senaratne

Chronic Pain Research Group, Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in BMC Medicine
Verified
Journal Article
Open access
PDF file
DSDhaneesha N. S. Senaratne
Dhaneesha N. S. Senaratne
BTBhushan Thakkar
Bhushan Thakkar
BSBlair H. Smith
Blair H. Smith
THTim G. Hales
Tim G. Hales
LMLouise Marryat
Louise Marryat
LCLesley A. Colvin
Lesley A. Colvin
Background: Adverse childhood experiences (ACEs) have been implicated in the aetiology of a range of health outcomes, including multimorbidity. In this systematic review and meta-analysis, we aimed to identify, synthesise, and quantify the current evidence linking ACEs and multimorbidity. Methods: We searched seven databases from inception to 20 July 2023: APA PsycNET, CINAHL Plus, Cochrane CENTRAL, Embase, MEDLINE, Scopus, and Web of Science. We selected studies investigating adverse events occurring during childhood (< 18 years) and an assessment of multimorbidity in adulthood (≥ 18 years). Studies that only assessed adverse events in adulthood or health outcomes in children were excluded. Risk of bias was assessed using the ROBINS-E tool. Meta-analysis of prevalence and dose–response meta-analysis methods were used for quantitative data synthesis. This review was pre-registered with PROSPERO (CRD42023389528). Results: From 15,586 records, 25 studies were eligible for inclusion (total participants = 372,162). The prevalence of exposure to ≥ 1 ACEs was 48.1% (95% CI 33.4 to 63.1%). The prevalence of multimorbidity was 34.5% (95% CI 23.4 to 47.5%). Eight studies provided sufficient data for dose–response meta-analysis (total participants = 197,981). There was a significant dose-dependent relationship between ACE exposure and multimorbidity (p < 0.001), with every additional ACE exposure contributing to a 12.9% (95% CI 7.9 to 17.9%) increase in the odds for multimorbidity. However, there was heterogeneity among the included studies (I2 = 76.9%, Cochran Q = 102, p < 0.001). Conclusions: This is the first systematic review and meta-analysis to synthesise the literature on ACEs and multimorbidity, showing a dose-dependent relationship across a large number of participants. It consolidates and enhances an extensive body of literature that shows an association between ACEs and individual long-term health conditions, risky health behaviours, and other poor health outcomes.

8 October 2025 in European journal of pain
Verified
Journal Article
Open access
ILIan‐Ju Liang
Ian‐Ju Liang
DSDhaneesha N. S. Senaratne
Dhaneesha N. S. Senaratne
BSBlair Smith
Blair Smith
Background and Objective: Chronic pain is a major global health challenge with substantial individual and societal burden. Epidemiological studies are essential for understanding the scale of the problem and identifying approaches to management. However, they reveal wide variation in reported prevalence, largely due to variations in defining and phenotyping of pain, with estimates spanning roughly 10%–50% depending on wording, recall period, severity thresholds, sampling and ascertainment mode. This paper discusses phenotyping approaches in pain epidemiology, highlighting the need for pre‐specified, transparent case definitions with harmonisation to improve comparability and reproducibility across studies. Methods: We drew from epidemiological literature on chronic pain phenotyping, focusing on methodological approaches. Examples of successful phenotyping strategies from large cohorts and consortia were identified to illustrate scalable and reproducible methods. Results: We identified ‘broad and shallow’ versus ‘deep and narrow’ approaches to phenotyping, and how they form part of a pyramid model. We explored this further using neuropathic pain as a worked example, with reference to the International Association for the Study of Pain's Special Interest Group on Neuropathic Pain (NeuPSIG) grading system for neuropathic pain and the Neuropathic Pain Phenotyping by International Consensus (NeuroPPIC) project, which aimed to offer a standardised and scalable phenotype suitable for epidemiological and genetic research. We also briefly reviewed other, modern approaches to phenotyping that have been developed, which combine large population samples, data integration and advanced statistical modelling, with the promise of enhanced comparability, and replication. Conclusions: Consensus on phenotyping is needed. We have illustrated a structured, scalable approach to standardised phenotyping, supporting data integration, comparability and replication. Significance Statement: This review highlights the critical importance of standardised phenotyping in chronic pain epidemiology. We introduce the pyramid model as a framework addressing key methodological gaps. Enabling scalable and reproducible phenotyping strengthens the foundation for future research and clinical translation, ultimately improving outcomes for people living with pain.

15 July 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
HTHarriet E. Taylor
Harriet E. Taylor
JSJoseph C. Salf
Joseph C. Salf
CRCharlotte R. Roper-Marchand
Charlotte R. Roper-Marchand
DSDhaneesha N.S. Senaratne
Dhaneesha N.S. Senaratne
BSBlair Smith
Blair Smith
JGJacob George
Jacob George
An association between persistent pain and blood pressure is increasingly recognised but is not fully understood. In this systematic review, we aimed to establish whether chronic pain (CP) is associated with a diagnosis of hypertension (HTN). After prospective registration (PROSPERO ID: CRD42025629486), we searched six databases from inception until January 8, 2025, for studies investigating the association between CP and HTN. Title and abstract screening, full-text review, data extraction, and risk of bias assessment were performed by two independent reviewers. Study quality assessment used the Risk of Bias In Non-randomised Studies of Exposures (ROBINS-E) tool. Meta-analysis was conducted using a random effects model. From 7973 records, we identified 23 eligible studies for inclusion, of which 20 provided suitable data for meta-analysis (total participants n=1 594 264). The pooled odds ratio for HTN in people with CP compared with controls was 1.66 (95% confidence interval [CI] 1.28-2.15) with high inter-study heterogeneity (I2=99.8%, Cochran Q=10 132, p<0.001). For specific pain conditions, the pooled odds ratio for HTN was 1.38 (95% CI 1.20-1.58, n = 374 234, heterogeneity: I2=65.1%, Cochran Q=14.34, p=0.014) in people with chronic, widespread pain, and 1.56 (95% CI 1.37-1.79, n=477 681, heterogeneity: I2=0%, Cochran Q=0.17, p=0.92) in people with chronic headache. There was no association between HTN and musculoskeletal pain, lower back pain, or gender. In line with a growing body of evidence in this field, this systematic review and meta-analysis confirms an association between chest pain and hypertension. Further research is warranted to understand this association and elucidate any mediating factors. PROSPERO (CRD42025629486).

22 October 2024 in British Journal of Anaesthesia
Verified
Journal Article
Open access
DSDhaneesha N.S. Senaratne
Dhaneesha N.S. Senaratne
MKMia Koponen
Mia Koponen
KBKaren Barnett
Karen Barnett
BSBlair Smith
Blair Smith
THTim G. Hales
Tim G. Hales
LCLesley A. Colvin
Lesley A. Colvin
There is well-established evidence linking adverse childhood experiences (ACEs) and chronic pain in adulthood. It is less clear how ACE exposure might influence the response to chronic pain treatment. In this systematic review, we synthesise the literature assessing the impact of ACE exposure on outcomes relating to the use, benefits, and harms of analgesic medications (analgesia-related outcomes). We searched seven databases from inception to September 26, 2023, for studies investigating adverse events in childhood (<18 yr) and any analgesia-related outcome during adulthood (≥18 yr). Title/abstract screening, full-text review, data extraction, and risk of bias assessment were performed independently by two authors. Given the high degree of study heterogeneity, a narrative synthesis was performed. From 7531 records, 66 studies met inclusion criteria, involving 137 395 participants. Analgesia-related outcomes were classed into six categories: use of analgesics (n=12), analgesic side-effects (n=4), substance misuse (n=45), lifetime drug overdose (n=2), endogenous pain signalling (n=4), and other outcomes (n=2). No studies assessed the effect of ACE exposure on the potential benefits of analgesics. ACE exposure was associated with greater use of analgesic medication, higher incidence of analgesic medication side-effects, greater risk and severity of substance misuse, greater risk of drug overdose, and greater risk of attempted suicide in opioid dependency. Adverse childhood experience exposure is associated with poor analgesia-related outcomes, so individual assessment adverse childhood experiences is important when considering the treatment of chronic pain. However, significant gaps in the literature remain, especially relating to the use and harms of non opioid analgesics. CRD42023389870 (PROSPERO).

27 November 2025 in British Journal of Anaesthesia
Verified
Journal Article
Open access
MKMia E. Koponen
Mia E. Koponen
DSDhaneesha N.S. Senaratne
Dhaneesha N.S. Senaratne
HHHarry L. Hébert
Harry L. Hébert
BSBlair Smith
Blair Smith
LCLesley A. Colvin
Lesley A. Colvin
Pharmacoepidemiological studies show that large proportions of people with neuropathic pain are not prescribed the recommended medications, do not adhere well to these medications, and often discontinue the treatment within 6 months. Identifying what predicts these outcomes can inform a strategy to ensure that people with neuropathic pain are prescribed recommended medication and continue their treatment when appropriate. We carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with neuropathic pain. Electronic searches were conducted in Embase, PubMed, Web of Science, and CINAHL Plus. We identified 69 relevant studies and divided them into non-mutually exclusive categories based on the outcomes they had investigated. There were 53 studies on prescribing, 14 on adherence, and 27 on discontinuation. Predictors associated with being prescribed recommended neuropathic pain medications included having a mental health disorder, diabetes mellitus, and White race. Predictors associated with better adherence included being prescribed serotonin-norepinephrine reuptake inhibitors compared with gabapentinoids or tricyclic antidepressants, dose titration, and implementing a medicine reminder. Predictors associated with a higher likelihood of discontinuation included being prescribed tricyclic antidepressants rather than other antidepressants and having a combination of neuropathic pain medications rather than monopharmacotherapy. There is a need to focus on improving neuropathic pain medication prescribing for ethnic minorities and people without diabetes mellitus. Adherence can be improved by using dose titration and medicine reminders. Prescribing monopharmacotherapy rather than combination pharmacotherapy for neuropathic pain could result in better treatment persistence. PROSPERO (CRD42023464307).

7 January 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
DSDhaneesha N S Senaratne
Dhaneesha N S Senaratne
BSBlair Smith
Blair Smith
THTimothy G Hales
Timothy G Hales
LMLouise Marryat
Louise Marryat
LCLesley A Colvin
Lesley A Colvin
Introduction Exposure to adverse childhood experiences (ACEs) is associated with a range of poor long-term health outcomes, including multimorbidity and chronic pain. Epidemiological evidence underpins much of this relationship; however, psychophysical testing methods, such as quantitative sensory testing (QST), may provide valuable insights into potential mechanisms. Previous studies have shown inconsistent links between ACEs and QST, but the QST profiles of people with multimorbidity have not been reported. We hypothesise that exposure to ACEs is associated with lowered QST thresholds (ie, experience of pain with milder stimuli) and that this association is stronger in adults with multimorbidity and/or chronic pain. The ACE-MAP study is a cross-sectional feasibility study with the primary aim of assessing the feasibility and acceptability of the proposed study procedures. The secondary aim is to generate preliminary data to understand the impact of ACEs on QST thresholds. Methods and analysis We plan to recruit 40 participants, with 10 in each of the following groups: (1) chronic pain with multimorbidity; (2) chronic pain without multimorbidity; (3) multimorbidity without chronic pain; and (4) controls. Participants will complete a series of questionnaires (including on ACEs, chronic pain and long-term conditions) and will then take part in QST assessments. The primary study outcomes will include measures of feasibility and acceptability of the proposed study design. The secondary study outcomes will include exploratory analysis on the relationship between ACEs and QST thresholds. Ethics and dissemination The study was approved by the Scotland B Research Ethics Committee (reference: 24/SS/0031). Results from the study will be presented at scientific conferences, published in a peer-reviewed journal and shared with patients and members of the public through other media streams. Trial registration number ISRCTN10049430.